Trade

with

Ligand Pharmaceuticals Inc
(NASDAQ: LGND)
AdChoices
50.67
+0.02
+0.04%
After Hours :
50.67
0.00
0.00%

Open

50.79

Previous Close

50.65

Volume (Avg)

258.48k (442.65k)

Day's Range

49.74-51.36

52Wk Range

41.99-80.42

Market Cap.

1.05B

Dividend Rate ( Yield )

-

Beta

1.55

Shares Outstanding

20.78M

P/E Ratio (EPS)

144.93 (0.35)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 48.97M

    • Net Income

    • 11.42M

    • Market Cap.

    • 1.05B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 13.85

    • PEG (Price/Earnings Growth) Ratio

    • 0.69

    • Beta

    • 1.55

    • Forward P/E

    • 20.83

    • Price/Sales

    • 20.04

    • Price/Book Value

    • 16.39

    • Price/Cash flow

    • 59.17

      • EBITDA

      • 17.61M

      • Return on Capital %

      • 7.54

      • Return on Equity %

      • 14.54

      • Return on Assets %

      • 7.54

      • Book Value/Share

      • 3.09

      • Shares Outstanding

      • 20.78M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 77.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • 2.18

        • Cashflow Estimate

        • 3.04

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 10.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -56.90

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 12.39

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 86.20

            • 82.75

            • Pre-Tax Margin

            • 13.67

            • 39.38

            • Net Profit Margin

            • 13.85

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 92.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -18.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 1.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 1.54

              • 2.92

              • Quick Ratio

              • 1.37

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.56

              • 2.21

              • Book Value/Share

              • 3.09

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 142.86

                • 196.08

                • P/E Ratio 5-Year High

                • 229.81

                • 634.30

                • P/E Ratio 5-Year Low

                • 23.26

                • 124.82

                • Price/Sales Ratio

                • 19.88

                • 9.12

                • Price/Book Value

                • 16.26

                • 8.26

                • Price/Cash Flow Ratio

                • 59.17

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 14.54

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 7.54

                        (2.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 12.27

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 376.10k

                      • 117.08k

                      • Inventory Turnover

                      • 4.86

                      • 1.48

                      • Asset Turnover

                      • 0.54

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      14.94M
                      Operating Margin
                      30.51
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      59.17
                      Ownership

                      Institutional Ownership

                      98.03%

                      Top 10 Institutions

                      51.19%

                      Mutual Fund Ownership

                      47.85%

                      Float

                      77.39%

                      5% / Insider Ownership

                      6.49%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,270,943

                      • -8.14

                      • 6.12

                      • PowerShares Dynamic Pharmaceuticals Port

                      •  

                        778,281

                      • 0.00

                      • 4.04

                      • iShares Core S&P Small-Cap (AU)

                      •  

                        379,266

                      • 0.79

                      • 1.95

                      • RS Select Growth Fund

                      •  

                        356,370

                      • -0.34

                      • 1.72

                      • SPDR® S&P Biotech ETF

                      •  

                        337,477

                      • 3.60

                      • 1.74

                      • iShares Russell 2000 (AU)

                      •  

                        320,755

                      • -1.02

                      • 1.65

                      • Vanguard Total Stock Mkt Idx

                      •  

                        294,835

                      • 2.81

                      • 1.42

                      • iShares Nasdaq Biotechnology

                      •  

                        275,886

                      • -0.69

                      • 1.42

                      • RS Small Cap Growth Fund

                      •  

                        273,800

                      • 7.92

                      • 1.32

                      • Vanguard Extended Market Index Fund

                      •  

                        176,172

                      • -8.89

                      • 0.85

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        1,718,486

                      • +3.23%

                      • 8.27

                      • Bvf Inc

                      •  

                        1,408,599

                      • -46.36%

                      • 6.78

                      • RS Investment Management Co. LLC

                      •  

                        1,392,185

                      • +13.88%

                      • 6.70

                      • BlackRock Fund Advisors

                      •  

                        1,298,901

                      • -4.14%

                      • 6.25

                      • Knott David M

                      •  

                        1,249,766

                      • 0.00%

                      • 6.01

                      • Vanguard Group, Inc.

                      •  

                        1,043,782

                      • +6.05%

                      • 5.02

                      • Blair William & Co

                      •  

                        843,711

                      • -9.92%

                      • 4.06

                      • State Street Corp

                      •  

                        571,984

                      • -2.97%

                      • 2.75

                      • Cardinal Capital Management Llc

                      •  

                        568,199

                      • -3.24%

                      • 2.73

                      • Invesco PowerShares Capital Mgmt LLC

                      •  

                        545,116

                      • -14.79%

                      • 2.62

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company...more has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Pro...moremacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.lessless

                      Key People

                      Mr. John L. Higgins

                      CEO/President/Director

                      Dr. John W. Kozarich,PhD

                      Chairman of the Board/Director

                      Nishan de Silva

                      Vice President, Divisional/CFO

                      Mr. Matthew W. Foehr

                      COO/Executive VP

                      Charles S. Berkman

                      Vice President/General Counsel/Secretary

                      • Ligand Pharmaceuticals Inc

                      • 11119 North Torrey Pines Road

                      • La Jolla, CA 92037

                      • USA.Map

                      • Phone: +1 858 550-7500

                      • Fax: -

                      • ligand.com

                      Incorporated

                      1987

                      Employees

                      20

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: